S100P promotes pancreatic cancer growth, survival, and invasion - PubMed (original) (raw)

S100P promotes pancreatic cancer growth, survival, and invasion

Thiruvengadam Arumugam et al. Clin Cancer Res. 2005.

Abstract

Purpose: In the current study, we examined the functional significance and mechanism of action of S100P in pancreatic cancer cells.

Experimental design: S100P levels were increased in Panc-1 cells, which do not express S100P, by transfection with an S100P cDNA and S100P levels were reduced in BxPC3 cells, which express high levels of S100P, by small interfering RNA gene silencing. Effects of these manipulations on cell proliferation, resistance to apoptotic insults, cell migration, and invasion were estimated in vitro using standard assays. The influences of S100P on tumor growth in vivo were studied using xenograft mouse models. To identify the mechanisms involved in these responses, coimmunoprecipitation studies were conducted with S100P with receptor for advanced glycation end products (RAGE) and the effects of inhibiting RAGE using an antagonistic peptide were analyzed.

Results: S100P levels correlated with the rates of cell proliferation, survival, migration, and invasion in both cell models in vitro. In vivo, increased S100P levels increased the growth of tumors in mice with s.c.-implanted Panc-1 cells and decreased S100P levels decreased tumor growth after orthotopic implantation of BxPC-3 cells. A direct interaction between S100P and RAGE was indicated by coimmunoprecipitation of these molecules from pancreatic cancer cells. A RAGE antagonist peptide inhibited this interaction and also inhibited the biological effects of S100P on these cells in vitro.

Conclusions: These data suggest that S100P plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Thus, interference with S100P may provide a novel approach for treatment of pancreatic cancer.

PubMed Disclaimer

Cited by

Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics.
Logsdon CD, Arumugam T, Ramachandran V. Logsdon CD, et al. Am J Physiol Gastrointest Liver Physiol. 2015 Sep 1;309(5):G283-91. doi: 10.1152/ajpgi.00169.2015. Epub 2015 Jul 9. Am J Physiol Gastrointest Liver Physiol. 2015. PMID: 26159697 Free PMC article. Review.
RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review.
Faruqui T, Khan MS, Akhter Y, Khan S, Rafi Z, Saeed M, Han I, Choi EH, Yadav DK. Faruqui T, et al. Int J Mol Sci. 2022 Dec 23;24(1):266. doi: 10.3390/ijms24010266. Int J Mol Sci. 2022. PMID: 36613714 Free PMC article. Review.
Prognostic significance of genetic alterations detected by high-density single nucleotide polymorphism array in gastric cancer.
Tada M, Kanai F, Tanaka Y, Sanada M, Nannya Y, Tateishi K, Ohta M, Asaoka Y, Seto M, Imazeki F, Yoshida H, Ogawa S, Yokosuka O, Omata M. Tada M, et al. Cancer Sci. 2010 May;101(5):1261-9. doi: 10.1111/j.1349-7006.2010.01500.x. Epub 2010 Jan 19. Cancer Sci. 2010. PMID: 20331625 Free PMC article.
Overcoming drug resistance in pancreatic cancer.
Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M. Long J, et al. Expert Opin Ther Targets. 2011 Jul;15(7):817-28. doi: 10.1517/14728222.2011.566216. Epub 2011 Mar 11. Expert Opin Ther Targets. 2011. PMID: 21391891 Free PMC article. Review.
Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma.
Li Z, Tang M, Ling B, Liu S, Zheng Y, Nie C, Yuan Z, Zhou L, Guo G, Tong A, Wei Y. Li Z, et al. J Mol Med (Berl). 2014 Mar;92(3):291-303. doi: 10.1007/s00109-013-1104-3. Epub 2013 Nov 27. J Mol Med (Berl). 2014. PMID: 24281831

S100P promotes pancreatic cancer growth, survival, and invasion - PubMed (original) (raw)